Lexicon Pharmaceuticals
LXRX
107 hedge funds and large institutions have $540M invested in Lexicon Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 22 closing their positions.
109% more call options, than puts
Call options by funds: $2.83M | Put options by funds: $1.36M
58% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 26
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
0% more funds holding
Funds holding: 107 → 107 (0)
2.47% less ownership
Funds ownership: 83.99% → 81.52% (-2.5%)
24% less capital invested
Capital invested by funds: $712M → $540M (-$171M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$4.43M |
| 2 |
BlackRock
New York
|
+$3.58M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.61M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.91M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.03M |
| 2 |
Morgan Stanley
New York
|
-$2.75M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.71M |
| 4 |
Renaissance Technologies
New York
|
-$1.22M |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$1.05M |
LXRX Hedge Fund Activity: Q2 2021 in Review
107 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2021, worth a combined $540M — down 24% from $712M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new LXRX positions and 22 closed out — a net gain of 1 holder — while 41 added to existing stakes and 26 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $4.43M. The largest seller was Fidelity Investments, cutting an estimated $8.03M.
- 107 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $540M of Lexicon Pharmaceuticals stock for Q2 2021, down 24% quarter-over-quarter.
- 23 funds opened new Lexicon Pharmaceuticals positions in Q2 2021 and 22 closed out, a net change of +1 holder.
- The largest Lexicon Pharmaceuticals buyer in Q2 2021 was JP Morgan Chase, an estimated $4.43M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2021 was Fidelity Investments, an estimated $8.03M sold.
Based on aggregated 13F filings for Q2 2021.